Kisqali (ribociclib) now available for some people diagnosed with early breast cancer through the Cancer Drugs Fund (CDF) in England

Today, the National Institute for Health and Care Excellence (NICE) published its preliminary optimised recommendation¹ for ribociclib to be used as adjuvant treatment in combination with an aromatase inhibitor for some patients with hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence. 

Ribocliclib will be made available in England through interim funding from the Cancer Drugs Fund (CDF) starting from April 24^th, while the final guidance is being prepared. This allows eligible patients to get access to an additional treatment option sooner.

Novartis recognises that NICE optimised recommendation provides access only to a subset of patients eligible for ribociclib as per Medicines and Healthcare products Regulatory Agency (MHRA) license issued on 1st February 2025. 

We welcome the initial decision from NICE, particularly the rapid access through CDF that provides an additional treatment option for certain patients. We are therefore committed to working closely with NICE and other stakeholders to ensure access to treatment for all early breast cancer patients eligible for ribociclib as per MHRA licence. We look forward to our future discussions ahead of the second committee meeting currently planned for June.